| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6220 |
Provisional Schedule
| Committee meeting | 09 July 2024 |
Project Team
| Project lead | Leena Issa |
Email enquiries
- If you have any queries please email TATeam7@nice.org.uk
Stakeholders
| Companies sponsors | AstraZeneca |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Roy Castle Lung Cancer Foundation |
| Professional groups | Association of Cancer Physicians |
| British Thoracic Oncology Group | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Associated public health groups | None |
| Comparator companies | Aspire Pharma (pemetrexed) (confidentiality agreement not signed, not participating) |
| Bristol Myers Squibb (nivolumab, paclitaxel) (confidentiality agreement signed, participating) | |
| Dr Reddy’s Laboratories (pemetrexed) (confidentiality agreement not signed, not participating) | |
| Eli Lilly (pemetrexed) (confidentiality agreement not signed, not participating) | |
| Genus Pharmaceuticals (pemetrexed) (confidentiality agreement not signed, not participating) | |
| Medac (oxaliplatin) (confidentiality agreement not signed, not participating) | |
| Merck Sharp & Dohme UK (pembrolizumab) (confidentiality agreement signed, participating) | |
| Pfizer (cisplatin, carboplatin, docetaxel, oxaliplatin, paclitaxel, pemetrexed) (confidentiality agreement not signed, not participating) | |
| Roche (atezolizumab) (confidentiality agreement signed, participating) | |
| Sandoz (cisplatin, pemetrexed) (confidentiality agreement not signed, not participating) | |
| Seacross Pharmaceuticals (paclitaxel, oxaliplatin, docetaxel) (confidentiality agreement not signed, not participating) | |
| Sun Pharmaceuticals (oxaliplatin) (confidentiality agreement not signed, not participating) | |
| Teva UK (paclitaxel) (confidentiality agreement not signed, not participating) | |
| Zentiva (pemetrexed) (confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| Scottish Medicines Consortium | |
| Welsh government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 30 November 2023 | The final scope was reissued on 30 November 2023 with a slight change to the population. |
| 21 November 2023 | Invitation to participate |
| 04 August 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during late November 2023 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early February 2024. |
| 19 July 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early January 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-March 2024. |
| 18 July 2023 | The scope of the first iteration of the NSCLC pathway will focus on development of the evidence synthesis of currently available data and the core model development. Therefore, ID6220, will be routed through a single technology appraisal route. More details about the NSCLC can be found on the webpage for ID6234. |
| 27 February 2023 | Please note that the evaluation of durvalumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer ID6220, will now be conducted via ID6234 considering multiple treatments for non-small-cell lung cancer. |
| 27 February 2023 | In progress. Scoping commencing |
| 23 November 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual